BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 19780703)

  • 21. Synthesis and biological evaluation of sulfonamidooxazoles and beta-keto sulfones: selective inhibitors of 11beta-hydroxysteroid dehydrogenase type I.
    Xiang J; Ipek M; Suri V; Massefski W; Pan N; Ge Y; Tam M; Xing Y; Tobin JF; Xu X; Tam S
    Bioorg Med Chem Lett; 2005 Jun; 15(11):2865-9. PubMed ID: 15911270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distinctive molecular inhibition mechanisms for selective inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
    Tu H; Powers JP; Liu J; Ursu S; Sudom A; Yan X; Xu H; Meininger D; Degraffenreid M; He X; Jaen JC; Sun D; Labelle M; Yamamoto H; Shan B; Walker NP; Wang Z
    Bioorg Med Chem; 2008 Oct; 16(19):8922-31. PubMed ID: 18789704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
    Su X; Vicker N; Trusselle M; Halem H; Culler MD; Potter BV
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):169-73. PubMed ID: 18775471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
    Anagnostis P; Katsiki N; Adamidou F; Athyros VG; Karagiannis A; Kita M; Mikhailidis DP
    Metabolism; 2013 Jan; 62(1):21-33. PubMed ID: 22652056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanisms of disease: Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome.
    Tomlinson JW; Stewart PM
    Nat Clin Pract Endocrinol Metab; 2005 Dec; 1(2):92-9. PubMed ID: 16929377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 2-amino-1,3-thiazol-4(5H)-ones as potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice.
    Johansson L; Fotsch C; Bartberger MD; Castro VM; Chen M; Emery M; Gustafsson S; Hale C; Hickman D; Homan E; Jordan SR; Komorowski R; Li A; McRae K; Moniz G; Matsumoto G; Orihuela C; Palm G; Veniant M; Wang M; Williams M; Zhang J
    J Med Chem; 2008 May; 51(10):2933-43. PubMed ID: 18419108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and 11β hydroxysteroid dehydrogenase 1 inhibition of thiazolidine derivatives with an adamantyl group.
    Kwon SW; Kang SK; Lee JH; Bok JH; Kim CH; Dal Rhee S; Jung WH; Kim HY; Bae MA; Song JS; Ha DC; Cheon HG; Kim KY; Ahn JH
    Bioorg Med Chem Lett; 2011 Jan; 21(1):435-9. PubMed ID: 21093259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery and structure-guided drug design of inhibitors of 11beta-hydroxysteroid-dehydrogenase type I based on a spiro-carboxamide scaffold.
    Lepifre F; Christmann-Franck S; Roche D; Leriche C; Carniato D; Charon C; Bozec S; Doare L; Schmidlin F; Lecomte M; Valeur E
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3682-5. PubMed ID: 19450980
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery and biological evaluation of adamantyl amide 11beta-HSD1 inhibitors.
    Webster SP; Ward P; Binnie M; Craigie E; McConnell KM; Sooy K; Vinter A; Seckl JR; Walker BR
    Bioorg Med Chem Lett; 2007 May; 17(10):2838-43. PubMed ID: 17350260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Azabicyclic sulfonamides as potent 11beta-HSD1 inhibitors.
    Shah U; Boyle CD; Chackalamannil S; Baker H; Kowalski T; Lee J; Terracina G; Zhang L
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1551-4. PubMed ID: 20149650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-based virtual screening for identification of novel 11beta-HSD1 inhibitors.
    Yang H; Shen Y; Chen J; Jiang Q; Leng Y; Shen J
    Eur J Med Chem; 2009 Mar; 44(3):1167-71. PubMed ID: 18653260
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and evaluation of piperidine urea derivatives as efficacious 11β-hydroxysteroid dehydrogenase type 1 inhibitors in diabetic ob/ob mice.
    Zhang L; Chen J; Ning M; Zou Q; Leng Y; Shen J
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2748-52. PubMed ID: 22440625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.
    Tomlinson JW
    Minerva Endocrinol; 2005 Mar; 30(1):37-46. PubMed ID: 15877012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening.
    Schuster D; Maurer EM; Laggner C; Nashev LG; Wilckens T; Langer T; Odermatt A
    J Med Chem; 2006 Jun; 49(12):3454-66. PubMed ID: 16759088
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
    Stimson RH; Walker BR
    Minerva Endocrinol; 2007 Sep; 32(3):141-59. PubMed ID: 17912154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 4-Methyl-5-phenyl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type I.
    Zhu Y; Olson SH; Hermanowski-Vosatka A; Mundt S; Shah K; Springer M; Thieringer R; Wright S; Xiao J; Zokian H; Balkovec JM
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3405-11. PubMed ID: 18440811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-based design of 7-azaindole-pyrrolidine amides as inhibitors of 11β-hydroxysteroid dehydrogenase type I.
    Valeur E; Christmann-Franck S; Lepifre F; Carniato D; Cravo D; Charon C; Bozec S; Musil D; Hillertz P; Doare L; Schmidlin F; Lecomte M; Schultz M; Roche D
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5909-14. PubMed ID: 22901389
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adamantyl carboxamides and acetamides as potent human 11β-hydroxysteroid dehydrogenase type 1 inhibitors.
    Su X; Halem HA; Thomas MP; Moutrille C; Culler MD; Vicker N; Potter BV
    Bioorg Med Chem; 2012 Nov; 20(21):6394-402. PubMed ID: 23040895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Piperazine sulfonamides as potent, selective, and orally available 11beta-hydroxysteroid dehydrogenase type 1 inhibitors with efficacy in the rat cortisone-induced hyperinsulinemia model.
    Xiang J; Wan ZK; Li HQ; Ipek M; Binnun E; Nunez J; Chen L; McKew JC; Mansour TS; Xu X; Suri V; Tam M; Xing Y; Li X; Hahm S; Tobin J; Saiah E
    J Med Chem; 2008 Jul; 51(14):4068-71. PubMed ID: 18578516
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.
    Su X; Vicker N; Potter BV
    Prog Med Chem; 2008; 46():29-130. PubMed ID: 18381124
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.